The Clinical Application of Neoantigens in Esophageal Cancer

Esophageal cancer (EC) is a common malignant tumor with poor prognosis, and current treatments for patients with advanced EC remain unsatisfactory. Recently, immunotherapy has been recognized as a new and promising approach for various tumors. EC cells present a high tumor mutation burden and harbor...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 11; p. 703517
Main Authors Gu, Yi-Min, Zhuo, Yue, Chen, Long-Qi, Yuan, Yong
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 27.07.2021
Subjects
adoptive cell therapy
cancer vaccine
esophageal cancer
immunotherapy
neoantigen
Oncology
Online AccessGet full text

Cover

More Information
Summary:Esophageal cancer (EC) is a common malignant tumor with poor prognosis, and current treatments for patients with advanced EC remain unsatisfactory. Recently, immunotherapy has been recognized as a new and promising approach for various tumors. EC cells present a high tumor mutation burden and harbor abundant tumor antigens, including tumor-associated antigens and tumor-specific antigens. The latter, also referred to as neoantigens, are immunogenic mutated peptides presented by major histocompatibility complex class I molecules. While current genomics and bioinformatics technologies have greatly facilitated the identification of tumor neoantigens, identifying individual neoantigens systematically for successful therapies remains a challenging problem. Owing to the initiation of strong, specific tumor-killing cytotoxic T cell responses, neoantigens are emerging as promising targets to develop personalized treatment and have triggered the development of cancer vaccines, adoptive T cell therapies, and combination therapies. This review aims to give a current understanding of the clinical application of neoantigens in EC and provide direction for future investigation.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Oncology
These authors have contributed equally to this work and share first authorship
Reviewed by: Enrique J. Arenas, Vall d’Hebron Institute of Oncology (VHIO), Spain; Matthias Bozza, German Cancer Research Center (DKFZ), Germany
Edited by: Jian-Guo Zhou, University of Erlangen Nuremberg, Germany
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2021.703517